medigraphic.com
ISSN 0016-3813 (Print)

2014, Number S2

<< Back Next >>

Gac Med Mex 2014; 150 (S2)

Current treatments for advanced stage melanoma

Ayala-Cortés AS, Garza-Rodríguez V, Ocampo-Candiani J

Language: Spanish
References: 78
Page: 144-155
PDF size: 273.30 Kb.


ABSTRACT

Melanoma has shown a greater increase in frequency as compared to other neoplasms, demonstrated by a 619% incidence increase in the USA from 1950 to the year 2000. Its treatment has always been a challenge, and once it has metastasized, there are no available curative regimens. In recent years considerable progress in the understanding of its pathophysiology and progression has been achieved; with the description of the genetic, molecular, and immunologic changes, new and specific drugs have been developed, with better response rates than conventional chemotherapy. Currently, a broad scope of therapeutic choices is available, although only eight are approved by the FDA. In the following literature review we present some of the better-known systemic treatment options for melanoma, from conventional chemotherapy, molecular (MAPK inhibitors) and immunomodulatory (interleukin-2, tumor necrosis factor alpha, cytotoxic T lymphocyte antigen-4 and programmed death-1 inhibitors) therapies, to miscellaneous options, among which are angiogenesis inhibitors, apoptosis modulators, vaccines, and radiotherapy.


REFERENCES

  1. DeVita VT, Jr., Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. Filadelfia: Lippincott Williams and Wilkins; 2005.

  2. Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD. 2008. [Internet]. Consultado el 10 de marzo de 2013. Disponible en: http://seer.cancer. gov/csr/1975_2005/.

  3. Tuong W, Cheng L, Amstrong A. Melanoma: Epidemiology, Diagnosis, Treatment and Outcomes. Dermatol Clin. 2012;30(1):113-24.

  4. De la Fuente-García A, Ocampo-Candiani J. Melanoma cutáneo. Gac Med Mex. 2010;146(2):126-35.

  5. Martínez H. El primer Consenso Nacional de Expertos en Melanoma. Gamo. 2005;4(2):11-3.

  6. Gutiérrez R, Cortés N. Confrontando al melanoma en el siglo XXI. Med Cutan Iber Lat Am. 2007;35(1):3-13.

  7. Hernández-Zárate S, Medina-Bojórquez A, López-Tello A, Alcalá-Pérez D. Epidemiología del cáncer de piel en pacientes de la Clínica de Dermato-oncología del Centro Dermatológico Dr. Ladislao de la Pascua. Estudio retrospectivo de los últimos ocho años. Dermatol Rev Mex. 2012;56(1):30-7.

  8. Harbst K, Staaf J, Måsbäck A, et al. Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Res. 2010;20(5):381-91.

  9. Viola JR, Rafael DF, Wagner E, Besch R, Ogris M. Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids. J Drug Deliv. 2013;2013:897348.

  10. Smalley K, McArthur G. The Current State of Targeted Therapy in Melanoma: This Time It’s Personal. Semin Oncol. 2012;39(2):204-14.

  11. Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2013;369(2):122-33.

  12. Satyamoorthy K, Herlyn M. Cellular and Molecular Biology of Human Melanoma. Cancer Biol Ther. 2002;1(1):14-7.

  13. Miller A, Mihm M. Mechanisms of Disease Melanoma. N Engl J Med. 2006;355(1):51-65.

  14. Haass N, Smalley K, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 2005;18(3):150-9.

  15. Kirkwood JM1, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7-17.

  16. Guida M, Pisconti S, Colucci G. Metastasic melanoma: the new era of targeted therapy. Expert Opin Ther Targets. 2012;16 Suppl 2:S61-70.

  17. Livingstone E, Zimmer L, Vaubel J, Schadendorf D. Current advances and perspectives in the treatment of advanced melanoma. J Dtsch Dermatol Ges. 2012;10(5):319-25. [Internet] Consultado el 24 de mayo de 2014. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23438377.

  18. Lee C, Collichio F, Ollila D, Moschos S. Historical review of melanoma treatment and outcomes. Clin Dermatol. 2013 Mar-Apr;31(2):141-7.

  19. Coit D, Andtbacka R, Anker C, et al. National Comprehensive Cancer Network (NCCN). Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(4):395-407.

  20. Davar D, Tarhini A, Kirkwood J. Adjuvant Therapy for Melanoma. Cancer J. 2012;18(2):192-202.

  21. Balch C, Gershenwald J, Soong S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(26):6199-206.

  22. Korn E, Liu P, Lee S, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-34.

  23. Fox MC, Lao CD, Schwartz JL, Frohm ML, Bichakjian CK, Johnson TM. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease. J Am Acad Dermatol. 2013;68(1):13.e1-13; quiz 26-8. [Internet] Consultado el 24 de mayo de 2014. Disponible en: http://www. ncbi.nlm.nih.gov/pubmed/23244384.

  24. Kim C, Lee C, Kovacic L, Shah A, Klasa R, Savage K. Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist. 2010;15(7):765-71.

  25. Patel P, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011; 47(10):1476-83.

  26. Avril M, Aamdal S, Grob J, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22(6):1118-25.

  27. Ives N, Stowe R, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007;25(34):5426-34.

  28. Hodi F, Soiffer R, Clark J, Finkelstein D, Haluska F. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002;25(3):283-6.

  29. Ribas A, Flaherty K. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8(7):426-33.

  30. Luke J, Hodi F. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res. 2012;18(1):9-14.

  31. Chapman P, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16.

  32. Sosman J, Kim K, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14.

  33. Mc Arthur G. Improved survival with vemurafenib in melanoma metastatic with BRAF V600E mutation. ECCO/ESMO. 2011 [abstract 28LBA].

  34. Drugs Approved for Melanoma. National Cancer Institute from The National Institutes of Health. 2014. [Internet] Consultado el 1 de abril de 2014. Disponible en: http://www.cancer.gov/cancertopics/druginfo/melanoma.

  35. Hauschild A, Grob J, Demidov L, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-65.

  36. Hauschild A, Agarwala S, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in 11 patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27(17):2823-30.

  37. Margolin K, Moon J, Flaherty L, et al. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res. 2012;18(4):1129-37.

  38. Kefford R, Arkenau H, Brown M. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol. 2010;2815s (suppl) [abstract 8503]. 2010;28:15s (suppl) [abstract 8503].

  39. Long G, Kefford R, Carr P. Phase 1/2 study of GSK2118436, a selective inhibitor of V600E mutant BRAF kinase: evidence of activity melanoma brain metastases. Ann Oncol. 2010;21:viii12 [abstract # LBA27].

  40. Flaherty K, Brose M, Schuchter L, Tuveson R, Schwartz L, Al. E. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary amtotumor activity in the expansion cohort of patients with metastatic melanoma (abstract). J Clin Oncol ASCO Annu Meet Proc (Post-Meeting Ed). 2004;22(14s):7507.

  41. Flaherty K, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-14.

  42. Delord J, Houede N, Awada A. First-in-human phase I safety, pharmacokinetic, and pharmacodynamic analysis of the oral MEK-inhibitor AS703026 (two regimens) in patients with advanced solid tumors. J Clin Oncol. 2010;28:205s [abstract 2504].

  43. Sullivan R, Lawrence D, Wargo J, Oh K, Gonzalez R, Piris A. Case 21- 2013: A 68-Year-Old Man with Metastatic Melanoma. N Engl J Med. 2013;369(2):173-83.

  44. King AJ, Arnone MR, Bleam MR, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/ MEK tool combination reduced skin lesions. PLoS One. 2013;8(7):e67583.

  45. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14(2):e60-9. [Internet] Consultado el 24 de mayo de 2014. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23369684.

  46. Lee B, Mukhi N, Liu D. Curent Management and novel agents for malignant melanoma. J Hematol Oncol. 2012;5:3.

  47. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-9.

  48. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-34.

  49. Liu LS, Colegio OR. Molecularly targeted therapies for melanoma. Int J Dermatol. 2013;52(5):523-30. [Internet] Disponible en: http://www.ncbi. nlm.nih.gov/pubmed/23590367.

  50. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182- 90. [Internet] Consultado el 24 de mayo de 2014. Disponible en: http:// www.ncbi.nlm.nih.gov/pubmed/23775962.

  51. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-16.

  52. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using highdose bolus interleukin 2. JAMA. 1994;271(12):907-13.

  53. Alatrash G, Hutson TE, Molto L, et al. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol. 2004;22(14):2891-900.

  54. Lawson D, Lee S, Tarhini A, Margolin K, Ernstoff M. Phase III cooperative group study of yeast-derived granulocyte macrophage colony stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III_IV melanoma. J Clin Oncol. 2010;28(15):612s [abstract 8504].

  55. Agarwala SS, Kirkwood JM. Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am. 1998;12(4):823.

  56. Slaton J, Perrotte P, Inoue K, Dinney C, Fidler I. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5(10):2726-34.

  57. Hersh E, O’Day S, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011;29(3):489-98.

  58. Hodi F, O’Day S, McDermott D, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.

  59. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26):2517-26.

  60. Millward M, Underhill C, Lobb S, et al. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer. 2013;108(10):1998-2004.

  61. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol. 2008 ASCO Annu Meet Proc (Post-Meeting Ed.). 2008;26:15s.

  62. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-44.

  63. Brahmer J, Drake C, Wollner I, et al. Phase I study of single-agent anti- programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-75.

  64. Dong H, Strome S, Salomao D, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(9):1039.

  65. Richards J, Bedikian A, Gonzalez R, Atkins M, Whitman E. High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial (abstract). J Clin Oncol ASCO Annu Meet Proc. 2005;23(16s (June 1 Supplement)):7543.

  66. Perez DG, Suman VJ, Fitch TR, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer. 2009;115(1):119-27.

  67. Kim K, Sosman J, Fruehauf J, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012;30(1):34-41.

  68. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006.;24(29):4738-45.

  69. Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of Radiation Therapy as Immune Activator in the Era of Modern Immunotherapy for Metastatic Malignant Melanoma. Am J Clin Oncol. 2014. [Epub ahead of print].

  70. Ibrahim R, Berman D, DePril V, et al. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. J Clin Oncol. 2011;29:(suppl) [abstract 8583].

  71. Olszanski AJ. Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Pharm. 2014;20(4):346-56. [Internet] Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24684639.

  72. Ma C, Armstrong A. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin- 2. J Dermatolog Treat. 2014;25(5):401-8.

  73. Baluna R, Vitetta E. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology. 1997;37(2-3):114-32.

  74. Sloot S, Fedorenko I, Smalley K, Gibney G. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? Expert Opin Pharmacother. 2014;15(5):589-92.

  75. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma. 2014.

  76. Sullivan RJ, Flaherty KT. Major therapeutic developments and current challenges in advanced melanoma. Br J Dermatol. 2014;170(1):36-44. [Internet] Consultado el 24 de mayo de 2014. Disponible en: http://www. ncbi.nlm.nih.gov/pubmed/24443912

  77. Ascierto P, Simeone E, Giannarelli D, Grimaldi A, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med. 2012;10:107.

  78. Smith F, Goff S, Klapper J, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother. 2007;30(1):130.




2020     |     www.medigraphic.com